BridgeBio Oncology Therapeutics reported net income of -$56.50M for the quarter ended Jun 2026. This income statement covers 11 quarters of results from Dec 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & Cost | |||||||||||
| Interest income | |||||||||||
| Interest Income - Total | 2.47M | 2.13M | 1.81M | 1.67M | 3.44M | 4.42M | 3.94M | 3.55M | |||
| Non-interest income | |||||||||||
| Investment Gain (Loss) | 0.00M | 0.00M | 0.00M | 0.00M | |||||||
| Non-Interest Income | 0.00M | 0.00M | 0.00M | 0.00M | |||||||
| Operating Items | |||||||||||
| Research & DevelopmentR&D | 17.89M | 19.54M | 20.64M | 27.44M | 35.05M | 38.07M | 39.80M | 49.23M | |||
| Selling, General & AdministrativeSG&A | 0.07M | 0.15M | 1.77M | 2.34M | 2.50M | 2.65M | 14.13M | 5.33M | 6.38M | 10.96M | |
| Operating ExpensesOpex | 0.07M | 0.15M | 19.66M | 21.88M | 23.14M | 30.09M | 49.18M | 43.41M | 46.18M | 60.19M | |
| Operating IncomeOp. Inc | -0.07M | -0.15M | -19.66M | -21.88M | -23.14M | -30.09M | -49.18M | -43.41M | -46.18M | -60.19M | |
| EBIT | -0.07M | -0.15M | -19.66M | -21.88M | -23.14M | -30.09M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Non-operating items | |||||||||||
| Non Operating Investment Income | -0.06M | -0.16M | -0.14M | -1.00M | |||||||
| Interest & Investment IncomeInt & Inv Inc | 1.21M | 2.44M | 2.55M | 2.25M | 1.99M | 2.07M | |||||
| Other Non Operating IncomeOther Non Op Inc. | -0.00M | -0.01M | -0.03M | 0.01M | -0.09M | -0.01M | |||||
| Non Operating IncomeNon Op. Inc. | 1.17M | 2.36M | 2.34M | 2.19M | 1.08M | 1.66M | 4.42M | 4.61M | 4.07M | 3.73M | |
| Net income details | |||||||||||
| EBT | 1.14M | 2.29M | -17.11M | -19.63M | -21.15M | -28.02M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Profit After TaxPAT | -15.44M | -21.82M | -17.32M | -19.70M | -22.05M | -28.43M | -44.76M | -38.80M | -42.11M | -56.50M | |
| Income from Continuing OperationsIncome (Continuing) | 1.14M | 2.29M | -17.11M | -19.63M | -21.15M | -28.02M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Consolidated Net IncomeConsol Net Inc. | 1.14M | 2.29M | -17.11M | -19.63M | -21.15M | -28.02M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Income towards Parent CompanyParent Net Inc | 1.14M | 2.29M | -17.11M | -19.63M | -21.15M | -28.02M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Net Income towards Common StockholdersNet Income | 0.77M | 1.78M | 1.88M | 1.58M | -0.39M | 0.74M | -49.18M | -43.41M | -46.18M | -60.19M | |
| Additional items | |||||||||||
| EPS (Basic) | 0.05 | 0.08 | 0.08 | 0.07 | -0.02 | 0.03 | -1.13 | -1.39 | -1.48 | -0.75 | |
| EPS (Diluted) | 0.05 | 0.08 | 0.08 | 0.07 | -0.02 | 0.04 | -1.13 | -1.39 | -1.48 | -0.75 | |
| Shares Outstanding | 4.00M | 14.19M | 23.51M | 23.51M | 21.16M | 18.91M | 23.51M | 43.49M | 31.14M | 31.14M | 80.05M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 4.00M | 14.47M | 23.51M | 23.51M | 21.24M | 18.91M | 18.91M | 43.49M | 31.14M | 31.14M | 80.05M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 16.12M | 35.56M | 41.50M | 41.50M | 21.16M | 41.47M | 62.38M | 62.38M | 62.38M | 80.12M | |
| EBITDA | -0.07M | -0.15M | -19.66M | -21.88M | -23.14M | -30.09M | -49.18M | -43.41M | -46.18M | -60.19M |